A viral-based individualized neoantigen vaccine as adjuvant treatment in resected head and neck squamous cell carcinoma: a randomized Phase I trial.
Ottensmeier C, Delord JP, Lalanne A, Jamet C, Le Gac AL, Bidet Huang K, Grellier B, Deforges J, Brandely M, Quéméneur E, Bastien B, Tavernaro A, Lacoste G, Schoettel V, Spring-Giusti C, Silvestre N, Marchand JB, Robin S, Dochy E, Ceppi M, Riva A, Yamagata N, Brattas P, Onoguchi K, Yamashita Y, Fontenelle H, Eggert Martinez M, Baker O, Jones T, Schache A, Piaggio E, Bendjama K, Lantz O, Le Tourneau C.
Ottensmeier C, et al.
Nat Commun. 2026 Aug 17;17(1):9863. doi: 10.1038/s41467-026-76667-1.
Nat Commun. 2026.
PMID: 42744798
Free PMC article.
Clinical Trial.
To this end, we developed TG4050, an individualized neoantigen therapeutic vaccine encoding up to 30 patient-specific predicted tumor neoantigens delivered by a Modified Vaccinia Ankara viral vector. ...The primary endpoint was safety, secondary endpoints inc …
To this end, we developed TG4050, an individualized neoantigen therapeutic vaccine encoding up to 30 patient-specific predicted …